Author of

• 25953

  +

  P2.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 965)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27306

    +

    P2.16-47 - “Improved aBVA Method” and “Anterior VAB Method” Result in Analogous Survival Benefits During Right Upper Lobectomy (ID 14321)

    16:45 - 18:00  |  Presenting Author(s): Jin Xia
    • Abstract
    • Slides

    Background
    

    As concluded in recent research, compared with “Anterior VAB Method” (dissecting pulmonary vessels first, followed by the bronchus), “Improved aBVA Method” (dissecting the posterior ascending arterial branch first, followed by the bronchus and vessels) during RUL would promote surgical feasibility and postoperative recovery for lung cancer patients. This study compared their long-term survival benefits basing on propensity score matching (PSM).

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    Consecutive lung cancer patients undergoing RUL were grouped into aBVA and VAB groups. PSM was conducted to reduce confounding bias between groups. After PSM, DFS and OS were estimated using the Kaplan–Meier method.

    4c3880bb027f159e801041b1021e88e8 Result
    

    

    397 patients were selected (167 in the aBVA group, and 230 in the VAB group). Before PSM, the histological subtypes, the mean number of dissected lymph node stations, operation time, amount of blood loss, number of used staplers, and the rate of conversion to thoracotomy during the operation, and the rate of pneumothorax and pneumonia, the mean duration of postoperative chest drainage after the operation were not balanced (P<0.05) between two groups. After PSM (caliper=0.02), 96 pairs of patients were successfully matched, and these 9 characters were all balanced (P>0.05) among the two groups. DFS and OS of the two groups were not significantly different (both P > 0.05). The median DFS and OS were comparable for all patients in the two groups (not arrived vs. 39 months, P > 0.05; both not arrived, P > 0.05). DFS and OS among patients with disease recurrence were not significantly different (both P > 0.05). The median DFS and OS were still similar in the two groups (16 vs. 11 months, P > 0.05; both not arrived, P > 0.05).

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    “aBVA Method” and “VAB Method” result in analogous survival benefits during RUL for lung cancer patients basing on PSM.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.